NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022 Benzinga Digital Content Studio

Digital Asset Direct by Agile Therapeutics, Inc.

Detroit, MI | October 21, 2022 11:00 AM Eastern Daylight Time

Meet Agile Therapeutics (NASDAQ: AGRX), a women's healthcare company with FDA approval for their weekly women's birth control patch, Twirla®, and who is actively working on a growth strategy to increase their revenue for Q3 of 2022. Learn more about Agile Therapeutics in this interview video with CEO, Al Altomari! Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Visit 👉 https://agiletherapeutics.com/

Contact Details

Matt Riley - Head of Investor Relations & Corporate Communications

mriley@agiletherapeutics.com

Company Website

https://agiletherapeutics.com/